Author

S. Klarenbeek

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:clustering· 1

Frequent Co-Authors

C. McLean· 2 shared A. Jurgens· 1 shared A. Martinez-Marti· 1 shared A. P. Drenth· 1 shared A. Villanueva· 1 shared C. L. G. J. Scheele· 1 shared C. Lancini· 1 shared C. S. Brambillasca· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. McLean

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer

J. M. Houthuijzen, R. de Bruijn, E. van der Burg, A. P. Drenth, E. Wientjens, T. Filipovic, E. Bullock, C. S. Brambillasca, M. Nieuwland, I. de Rink, F. van Diepen, S. Klarenbeek, R. Kerkhoven, V. Brunton, C. L. G. J. Scheele, , J. Jonkers

The paper identifies CD26-negative and CD26-positive tissue-resident fibroblasts as sources of distinct CAF subpopulations in breast cancer through single-cell transcriptomics and functional assays.

bioRxiv · Sep 27, 2022 · PreprintCancer Biology

Multiple Low Dose therapy: an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

J. M. Fernandes Neto, E. Nadal, S. N. Ooft, E. Bosdriesz, L. Farre, C. McLean, S. Klarenbeek, A. Jurgens, H. Hagen, L. Wang, E. Felip, A. Martinez-Marti, E. Voest, L. Wessels, O. van Tellingen, , R. Bernards

This paper shows that using multiple low doses of drugs targeting different components of a signaling pathway can effectively treat EGFR inhibitor-resistant NSCLC without resistance development.

bioRxiv · Oct 29, 2019Cancer Biology

Evolutionarily-conserved chromatin crosstalk generates a DOT1L-dose dependency in thymic lymphoma caused by loss of HDAC1

H. Vlaming, C. McLean, T. Korthout, M. F. Alemdehy, S. Henriks, C. Lancini, S. Palit, S. Klarenbeek, T. M. Molenaar, L. Hoekman, T. T. Schmidlin, M. Altelaar, T. v. Welsem, J.-H. Dannenberg, H. Jacobs, F. van Leeuwen

The paper identifies an evolutionarily-conserved interaction between HDAC1 and DOT1L that influences H3K79 methylation and contributes to thymic lymphoma development.

bioRxiv · Jan 10, 2019Cell Biology